Safety and efficacy of bexarotene in patients with relapsing-remitting multiple sclerosis (CCMR One): a randomised, double-blind, placebo-controlled, parallel-group, phase 2a study. (2021)
Attributed to:
UK Dementias Platform
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/s1474-4422(21)00179-4
PubMed Identifier: 34418398
Publication URI: http://europepmc.org/abstract/MED/34418398
Type: Journal Article/Review
Volume: 20
Parent Publication: The Lancet. Neurology
Issue: 9
ISSN: 1474-4422